Skip to main content

Advertisement

Selected expression profiling of full-length proteins and their variants in human plasma

Clinical Proteomics volume 1, pages7–16(2004)Cite this article

Article metrics

  • 385 Accesses

  • 18 Citations

Abstract

With increased interest in clinical proteomics—the comparative investigation of differential protein expression patterns for use in the diagnostic and prognostic assessment of disease states—the demand for techniques that can readily identify changes in select proteome components is greater than ever before. This article describes a targeted proteomics approach to recover and quantify C-reactive protein (CRP) directly from human plasma. CRP, a putative biomarker for cardiac health, was isolated from microliter volumes of human plasma by using novel proteomics tools that combine micro-scale affinity capture with matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) detection. Native CRP was analyzed along with serum amyloid P component (SAP) and retinol binding protein (RBP), that were intentionally targeted to generate a selected protein expression profile. A number of qualitative changes were readily observed within these profiles, including micro heterogeneity in the SAP glycan, C-terminally truncated versions of RBP, and detection of a novel truncated variant of CRP. After quantitative validation of increasing plasma CRP concentrations, the approach was applied to the analysis of eight plasma samples obtained from individuals with known medical histories. The result of the analyses are eight protein profiles, revealing increasing CRP levels that can be associated with individuals ailing from post-surgery inflammation, chronic rheumatoid arthritis, and recent acute myocardial infarction. The technique described in this article lays the foundation for selected protein profiling for use in biomarker discovery, as well as in clinical and diagnostic applications.

References

  1. 1

    Yanagisawa K, Shyr Y, Xu BJ, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003;362(9382):433–439.

  2. 2

    Petricoin EF, Ardekani AM, Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002;359(9306):572–577.

  3. 3

    Conrads TP, Zhou M, Petricoin EF, 3rd, Liotta L, Veenstra TD. Cancer diagnosis using proteomic patterns. Expert Rev Mol Diagn 2003; 3(4):411–420.

  4. 4

    Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002; 1(11):845–867.

  5. 5

    Diamandis EP. Point: Proteomic patterns in biological fluids: do they represent the future of cancer diagnostics? Clin Chem 2003;49(8): 1272–1275.

  6. 6

    Mann M, Hendrickson RC, Pandey A. Analysis of Proteins and Proteomes By Mass Spectrometry. Annu Rev Biochem 2001;70:437–473.

  7. 7

    Nelson RW, Krone JR, Bieber AL, Williams P. Mass-Spectrometric Immunoassay. Anal Chem 1995;67(7):1153–1158.

  8. 8

    Niederkofler EE, Tubbs KA, Kiernan UA, Nedelkov D, Nelson RW. Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins. J Lipid Res 2003;44(3):630–639.

  9. 9

    Tubbs KA, Nedelkov D, Nelson RW. Detection and quantification of beta-2-microglobulin using mass spectrometric immunoassay. Anal Biochem 2001;289(1):26–35.

  10. 10.

    Kiernan UA, Tubbs KA, Gruber K, et al. High-Throughput Protein Characterization Using Mass Spectrometric Immunoassay. Anal Biochem 2002;301(1):49–56.

  11. 11.

    Kiernan UA, Tubbs KA, Nedelkov D, Niederkofler EE, Nelson RW. Comparative phenotypic analyses of human plasma and urinary retinol binding protein using mass spectrometric immunoassay. Biochem Biophys Res Commun 2002;297(2):401–405.

  12. 12.

    Kiernan UA, Tubbs KA, Nedelkov D, Niederkofler EE, Nelson RW. Detection of novel truncated forms of human serum amyloid A protein in human plasma. FEBS Lett 2003; 537(1–3):166–170.

  13. 13.

    Kiernan UA, Tubbs KA, Nedelkov D, Niederkofler EE, McConnell E, Nelson RW. Comparative urine protein phenotyping using mass spectrometric immunoassay. J Proteome Res 2003;2(2):191–197.

  14. 14.

    Niederkofler EE, Tubbs KA, Gruber K, et al. Determination of beta-2 microglobulin levels in plasma using a high-throughput mass spectrometric immunoassay system. Anal Chem 2001;73(14):3294–3299.

  15. 15.

    Haverkate F, Thompson SG, Pyke SD, Gallimore JR, Pepys MB. Production of C-reactive protein and risk of coronary events in stable and unstable angina. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. Lancet 1997;349(9050): 462–466.

  16. 16.

    Liuzzo G, Baisucci LM, Gallimore JR, et al. Enhanced inflammatory response in patients with preinfarction unstable angina. J Am Coll Cardiol 1999;34(6):1696–1703.

  17. 17.

    Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98(8):731–733.

  18. 18.

    Tommasi S, Carluccio E, Bentivoglio M, et al. C-reactive protein as a marker for cardiac ischemic events in the year after a first, uncomplicated myocardial infarction. Am J Cardiol 1999;83(12):1595–1599.

  19. 19.

    Rost NS, Wolf PA, Kase CS, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001;32(11): 2575–2579.

  20. 20.

    Curb JD, Abbott RD, Rodriguez BL, et al. C-reactive protein and the future risk of thromboembolic stroke in healthy men. Circulation 2003;107(15):2016–2020.

  21. 21.

    Kuller LH, Tracy RP, Shaten J, Meilahn EN. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case-control study. Multiple Risk Factor Intervention Trial. Am J Epidemiol 2004;144(6):537–547.

  22. 22.

    Ferreiros ER, Boissonnet CP, Pizarro R, et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 1999;100(19):1958–1963.

  23. 23.

    Kushner I. The phenomenon of the acute phase response. Ann N Y Acad Sci 1982;389: 39–48.

  24. 24.

    Zimmerman MA, Selzman CH, Cothren C, Sorensen AC, Raeburn CD, Harken AH. Diagnostic implications of C-reactive protein. Arch Surg 2003;138(2):220–224.

  25. 25.

    Kushner I. C-reactive protein and atherosclerosis. Science 2002;297(5581):520–521.

Download references

Author information

Affiliations

  1. Intrinsic Bioprobes, Inc, 625 S. Smith Road Suite 22, 85281, Tempe, AZ

    • Urban A. Kiernan
    • , Dobrin Nedelkov
    • , Kemmons A. Tubbs
    • , Eric E. Niederkofler
    •  & Randall W. Nelson

Authors

  1. Search for Urban A. Kiernan in:

  2. Search for Dobrin Nedelkov in:

  3. Search for Kemmons A. Tubbs in:

  4. Search for Eric E. Niederkofler in:

  5. Search for Randall W. Nelson in:

Corresponding author

Correspondence to Randall W. Nelson.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Kiernan, U.A., Nedelkov, D., Tubbs, K.A. et al. Selected expression profiling of full-length proteins and their variants in human plasma. Clin Proteom 1, 7–16 (2004) doi:10.1385/CP:1:1:007

Download citation

Key Words

  • Relative quantification
  • MALDI-TOF MS
  • C-reactive protein
  • human plasma
  • protein expression profiles
  • immunoassay

Clinical Proteomics

ISSN: 1559-0275